Oncogenesis · 2015 · 124 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyChromatin BiologyMolecular OncologyCancer Cell SignalingEpigenetic Regulation In CancerSignal Transduction In CancerTargeted Cancer TherapyAnticancer ActivityAnticancer ChemotherapyCancer Cell Proliferation InhibitionHistone AcetylationHistone Acetyltransferase InhibitionHistone-lysine AcetylationNeuroblastoma Biology
We have previously described novel histone acetyltransferase (HAT) inhibitors that block neuroblastoma cell growth in vitro. Here we show that two selected pyridoisothiazolone HAT inhibitors, PU139 and PU141, induce cellular histone hypoacetylation and inhibit growth of several neoplastic cell lines originating from different tissues. Broader in vitro selectivity profiling shows that PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300, whereas PU141 is selective toward CBP and p300. The pan-inhibitor PU139 triggers caspase-independent cell death in cell culture. Both inhibitors block growth of SK-N-SH neuroblastoma xenografts in mice and the PU139 was shown to synergize with doxorubicin in vivo. The latter also reduces histone lysine acetylation in vivo at concentrations that block neoplastic xenograft growth. This is one of the very few reports on hypoacetylating agents with in vivo anticancer activity.
38
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
The language of covalent histone modifications
Brian D. Strahl, C. David Allis · Nature · 2000 · 8.6K citations
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary, Chanchal Kumar, Florian Gnad et al. · Science · 2009 · 4K citations · Full text